Trinity Biotech Regains Compliance with Nasdaq Listing Requirements
Trinity Biotech Enters Oncology Space with Acquisition of Prostate Cancer Focused EpiCapture
Trinity Biotech Appoints Global Life Sciences Leader as Chief Commercial Officer
Trinity Biotech Announces Increased Orders for TrinScreen HIV and Raises Guidance For 2024 Sales
Trinity Biotech Obtains an Extension to Demonstrate Compliance With Nasdaq Listing Requirements
Trinity Biotech Announces Q1 2024 Financial Results and Reiterates Guidance
Trinity Biotech Announces Fourth Quarter and Fiscal Year 2023 Financial Results Business Updates
Trinity Biotech Plc Finalizes Effective Date of ADS Ratio Change